HEC Pharma (1558 HK): Strong Performance to Continue as Flu Activity Is On Rise In China
614 Views04 Jan 2024 09:30
SUMMARY
- Yichang HEC Changjiang Pharma (1558 HK) is set to benefit from the recent upsurge in respiratory illness in China. The company commands ~90% share of anti-flu drug market in China.
- In 1H23, HEC Pharma’s revenue jumped 148% YoY to RMB3.2B, mainly due to spiking flu cases in China. A strong flu season in 4Q23, should boost H2 performance.
- Despite a 43% rally in HEC Pharma share price over the last six months, the shares are trading at forward P/E of just 4.8x.
Get started on the Smartkarma Research Network with a complimentary Preview Pass to:
- Unlock all research summaries
- Follow top, independent analysts
- Receive personalised alerts and emails
- Access Briefings, Analytics, and Events
Upgrade anytime to our paid plans for full-length research, real-time analyst discussions, and more.
Join a thriving community of 45,000+ investors, including the top global asset managers managing over $13trn in assets.
or
Already have an account? Sign In Now
Discussions
(Paid Plans Only)
Rising
Tina Banerjee
Global Healthcare Analyst
- HEC Pharma (1558 HK): Strong Performance to Continue as Flu Activity Is On Rise In China04 Jan 2024
- HEC Pharma (1558 HK): Robust 1H23 Performance on Flu Outbreak in China02 Oct 2023
- HEC Pharma (1558 HK): Core Product Saw Volume Recovery in 1H 2022; New Launches to Accelerate Growth27 Nov 2022
- Yichang HEC Changjiang Pharma (1558 HK): Multiple New Products Launches Bring New Opportunities24 Nov 2021
x